Angelos Stergiou: SELLAS Life Sciences Group

1
Angelos Stergiou
About SELLAS Life Sciences Group
2
Dr. Angelos M. Stergiou, MD, ScD h.c. is the CEO
and Vice Chairman of SELLAS Life Sciences Group,
which he founded with the intention to give back
to humanity through clinical research, discovery
and drug development. In recent news, Dr.
Angelos Stergiou and SELLAS Life Sciences Group
have received increasing media coverage as the
progression of the WT1 neoepitome
immunotherapeutic anti-cancer treatment and
vaccine continues to yield promising results.
3

• The points below will help you learn more about
  SELLAS Life Sciences Group and what the company
  is contributing to the world
• SELLAS Life Sciences Group. As a leading
  international biopharmaceutical company, SELLAS
  Life Sciences focuses on advancing various cancer
  therapies and developing diverse cancer programs.
  The company seeks to improve the lives of
  patients everywhere by commercializing
  cutting-edge cancer therapeutics.
• WT1 Neoepitope Immunotherapy. Named for the WT1
  antigen one of the most common antigens found
  in malignancies the WT1 anti-cancer treatment,
  called galinpepimut-S, consists of four
  synthetically heteroclitically modified peptide
  chains that are designed to induce patient immune
  response against the WT1 antigen. As of 2016,
  trial phases have shown promising survival
  benefits.

4
To learn more about the work of SELLAS Life
Sciences Group or Dr. Angelos Stergiou, visit
www.sellaslifesciences.com Also connected with
Angelos Stergiou through social
profiles https//twitter.com/drstergiou www.sco
op.it/t/angelos-stergiou https//plus.google.com/
116965580440240268259 www.facebook.com/Angelos-St
ergiou-1813027965638555/